Mycoplasma pneumoniae is a major human pathogen that causes both upper and lower respiratory infections, and is one of the leading causes of community-acquired pneumonia (CAP), accounting for 11–15% of CAP throughout the world (Brown et al.; Kishaba; Meyer Sauteur et al.; Saraya). M. pneumoniae is also one of the smallest free-living human pathogens, with a genome size of less than 700 genes (Spuesens et al.). In this volume of Frontiers we have explored few of many aspects related to this major human pathogen. The purpose of this topic was to thoroughly review and to create a body of knowledge encompassing both medical and biological information gathered in both the western world and Asia.
Saraya contributed a nice historical perspective on the discovery of M. pneumoniae and a few authors contributed an updated and fresh look on the clinical manifestations of M. pneumoniae (Kishaba; Meyer Sauteur et al.; Izumikawa; Narita; Tanaka; Parrott et al.). The unique epidemiological challenges presented by this pathogen include both outbreaks and the “Olympic” (3–5 years) intervals between epidemics, which reported here in both Japan and the UK (Brown et al.; Parrott et al.; Yamazaki and Kenri). Since its discovery, the main challenge for diagnostic labs and clinicians was its fastidious growth that led to a reliance on serology, and later on, amplification techniques for diagnosis. Two reviews cover diagnostics here (Diaz and Winchell, Loens and Ieven). An additional review combines the antibody response to epidemiological aspects as a means to explain the epidemiology (Dumke and Jacobs). Pathogenesis is covered by 2 topics: One on the bacterial aspect and the other on the host inflammatory response to M. pneumoniae infection (Miyata and Hamaguchi; Shimizu). Additionally, Spuesens et al. explored the possible role of genomics in elucidating the differentiation between sick and carrier patients. Obviously, for each infectious agent, treatment and cure is the goal, if prevention is not possible (yet). However, since M. pneumoniae is lacking a cell wall, antibiotic choices are limited to the use of macrolides and related antibiotics, tetracyclines and quinolones, and some of those classes have limited use in the pediatric populations (Meyer Sauteur et al.; Pereyre et al.). Pereyre et al. summarized the emerging macrolide resistance and Balish and Distelhorst explored the possible use of new agents in the future.
Obviously, not everything can be covered in depth and many of the topics explored here raise many new questions that remains to be answered, by the scientific community.
Statements
Author contributions
RN wrote the first draft; TSa, TSh, AV, and CB reviewed commented and edited the manuscript. All authors have approved the manuscript.
Acknowledgments
This work was part of the ESGMI—The ESCMID study group on mycoplasma infections initiative.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Summary
Keywords
Mycoplasma pneumoniae, mycoplasma infections, epidemiology, pneumonia, respiratory tract infections
Citation
Nir-Paz R, Saraya T, Shimizu T, Van Rossum A and Bébéar C (2017) Editorial: Mycoplasma pneumoniae Clinical Manifestations, Microbiology, and Immunology. Front. Microbiol. 8:1916. doi: 10.3389/fmicb.2017.01916
Received
01 September 2017
Accepted
20 September 2017
Published
29 September 2017
Volume
8 - 2017
Edited by
Yuji Morita, Aichi Gakuin University, Japan
Reviewed by
Gretchen Lynn Parrott, University of the Ryukyus, Japan
Updates
Copyright
© 2017 Nir-Paz, Saraya, Shimizu, Van Rossum and Bébéar.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ran Nir-Paz ran.nir-paz@mail.huji.ac.il
This article was submitted to Infectious Diseases, a section of the journal Frontiers in Microbiology
†ESGMI - The ESCMID Study Group on Mycoplasma Infections.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.